Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center (IMAGE)

University of Texas Health Science Center at San Antonio

Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center

Caption

Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, said results of the MOMENTUM phase 3 clinical trial of momelotinib show that the drug can address anemia, a serious problem in myelofibrosis (bone marrow cancer) treatment.

Credit

UT Health San Antonio

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.